Pharmacotherapy for Vascular Cognitive Impairment. (Q54440823)

29 May 2018

title

Pharmacotherapy for Vascular Cognitive Impairment. (English)

1 reference

29 May 2018

main subject

pharmacotherapy

0 references

cognitive dysfunction

1 reference

Muhammad U Farooq

1

1 reference

29 May 2018

Jiangyong Min

series ordinal

2

1 reference

29 May 2018

Christopher Goshgarian

series ordinal

3

1 reference

29 May 2018

Philip B Gorelick

series ordinal

4

1 reference

29 May 2018

publication date

1 September 2017

1 reference

29 May 2018

published in

CNS Drugs

1 reference

29 May 2018

volume

31

1 reference

29 May 2018

issue

9

1 reference

29 May 2018

page(s)

759-776

1 reference

29 May 2018

Stroke and Potentially Preventable Dementias Proclamation

cites work

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

World Stroke Day Proclamation 2015: Call to Preserve Cognitive Vitality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Diagnostic criteria for vascular cognitive disorders: a VASCOG statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

William M. Feinberg Lecture: Cognitive vitality and the role of stroke and cardiovascular disease risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

The projected effect of risk factor reduction on Alzheimer's disease prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Vascular cognitive impairment and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

A comparison of health expectancies over two decades in England: results of the Cognitive Function and Ageing Study I and II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Incidence of Dementia over Three Decades in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

New insights into the dementia epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Early adult to midlife cardiovascular risk factors and cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Risk factors and preventive interventions for Alzheimer disease: state of the science

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Sleep characteristics and cognitive impairment in the general population: The HypnoLaus study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Consensus statement for diagnosis of subcortical small vessel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Stroke and Alzheimer disease: fellow travelers or partners in crime?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Dementia: from muddled diagnoses to treatable mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

The Vascular Impairment of Cognition Classification Consensus Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Factors associated with cognitive evaluations in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

The Effect of Different Diagnostic Criteria on the Prevalence of Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Survival in Alzheimer's disease and vascular dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Predictors of survival in clinically diagnosed Alzheimer's disease and multi-infarct dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

A controlled study of survival with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Survival and cause of death in Alzheimer's disease and multi-infarct dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Predictors of survival in African American patients with AD, VaD, or stroke without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Blood pressure and the prevention of cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Underlying cause of death in demented and non-demented elderly Canadians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Survival study of vascular dementia in Rochester, Minnesota

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Previous and incident dementia as risk factors for mortality in stroke patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Mortality in patients with dementia after ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Mortality in elderly Canadians with and without dementia: a 5-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Cognitive and functional decline in African Americans with VaD, AD, and stroke without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

The pattern of neuropsychological deficits in Vascular Cognitive Impairment-No Dementia (Vascular CIND).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Neuropsychological predictors of incident dementia in patients with vascular cognitive impairment, without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Cholinergic denervation in a pure multi-infarct state: observations on CADASIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Donepezil in vascular dementia: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Donepezil in vascular dementia: combined analysis of two large-scale clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Galantamine treatment of vascular dementia: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Rivastigmine in subcortical vascular dementia: an open 22-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Citicoline (Cognizin) in the treatment of cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Long-term treatment with citicoline may improve poststroke vascular cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Calcium channel blockers and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Nilvadipine prevents cognitive decline of patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Neuroprotective Effects of Simvastatin and Cilostazol in L-Methionine-Induced Vascular Dementia in Rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Clinical Trials in Dementia with Propentofyllinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Naftidrofuryl in the treatment of vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Monetary costs of dementia in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Vascular disease and dementias: paradigm shifts to drive research in new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Vascular contributions to cognitive impairment and dementia including Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

Translational models for vascular cognitive impairment: a review including larger species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

First translational 'Think Tank' on cerebrovascular disease, cognitive impairment and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0459-3

21 January 2018

Memantine for dementia

1 reference

12 December 2020

Naftidrofuryl in the treatment of mild senile dementia. A double-blind study

1 reference

12 December 2020

The neurochemistry of vascular dementia.

1 reference

12 December 2020

Vinpocetine for cognitive impairment and dementia

1 reference

12 December 2020

Vascular Cognitive Impairment

1 reference

12 December 2020

Piracetam for dementia or cognitive impairment

1 reference

12 December 2020

Vascular dementias in the elderly

1 reference

12 December 2020

Understanding and treating vascular cognitive impairment

1 reference

12 December 2020

The effect of cilostazol and aspirin pre-treatment against subsequent transient focal cerebral ischemia in rat

1 reference

12 December 2020

Rivastigmine for vascular cognitive impairment

1 reference

12 December 2020

Prevention of vascular dementia

1 reference

12 December 2020

Progression of impairment in patients with vascular cognitive impairment without dementia

1 reference

12 December 2020

Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly

1 reference

12 December 2020

Galantamine for vascular cognitive impairment

1 reference

12 December 2020

Huperzine A for vascular dementia

1 reference

12 December 2020

10.1007/S40263-017-0459-3

Identifiers

DOI

1 reference

29 May 2018

1 reference

29 May 2018